+989222938678 info@ermateb.com
آیکون وبسایت ارماطب Ermateb

Could aspirin diminish the risk of fatality risk in covid-19 cases?

2021-07-14 11:40:16

Dr. Fariba Azadikhah
Reviewed by:
Dr. Fariba Azadikhah

There have been 86 million cases of corona and around 4 million deaths registered to the WHO. In severely affected in-hospital COVID-19 patients, an estimated mortality rate of 11.5% has been reported in a recent study.

According to the researches, the pathogenesis of covid-19 is usually accompanied by a weakened immune system, extreme inflammation, and cardiopulmonary thrombosis. With this observation scientists thought that aspirin may reduce the severity in covid-19 with its anti-platelet aggregation, anti-inflammatory, and anti-lung injury effects.

The data combined from 5 studies revealed that aspirin intake is associated with a 53% reduction in all-cause mortality in COVID-19 patients. In the case of hospitalized COVID-19 patients, the evaluation revealed that the use of aspirin is related to a 49% cutback in in-hospital mortality.  

Aspirin has the triple effects of inhibiting virus replication, anticoagulant, and anti-inflammatory, but it has not received attention in the treatment and prevention of nursing care plans.

 

In summary, the early use of aspirin in covid-19 patients, which has the effects of inhibiting virus replication, anti-platelet aggregation, anti-inflammatory, and anti-lung injury, is expected to reduce the incidence of severe and critical patients, shorten the length of hospital duration and reduce the incidence of cardiovascular complications.

Resource

Share your comments and questions with us
If you need our experts to answer you, send us your WhatsApp number along with your country code
Your message has been registered successfully, and it will be displayed after confirmation
×